Figure 2 provides information on the incidences of expression of CCL2, CCL5, TNFα and IL-1β in normal breast epithelial cells of Benign patients, and in the tumor cells in patients diagnosed with DCIS, IDC-no-relapse and IDC-with-relapse. Here, CCL2 is linked to ductal breast carcinoma in situ.